SCHEDULE: Alyeska Investment Group Discloses 4.49% Stake in Spruce

Alyeska Investment Group, L.P. and affiliates have reported a 4.49% beneficial ownership stake in Spruce Biosciences, Inc. as of March 31, 2026.

Summary

• Alyeska Investment Group, L.P., Alyeska Fund GP, LLC, and Anand Parekh filed a Schedule 13G reporting beneficial ownership of 61,670 shares of Spruce Biosciences, Inc. common stock.
• The reported stake represents 4.49% of the company's outstanding common stock.
• The holdings consist of 21,671 shares of common stock, 9,999 shares issuable upon warrant exercise, and 30,000 shares acquired via private placement.
• The filing confirms the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral disclosure of institutional ownership, reflecting standard portfolio management activity rather than a change in corporate strategy.

Positives

• Institutional investment from Alyeska Investment Group indicates professional interest in the company's equity.
• The acquisition includes shares from a private placement, suggesting participation in company capital raising efforts.

Negatives

• The reporting persons hold less than 5% of the company's outstanding shares, which is below the threshold typically associated with significant activist influence.

Risks

• The investment includes warrants, which are subject to exercise conditions and market price fluctuations.
• The company's share count is relatively low (1,372,043 shares), which may lead to higher volatility in share price.

Future Outlook

The filing does not provide forward-looking guidance regarding the company's operations, but confirms the reporting persons' intent to hold the securities in the ordinary course of business without seeking control.

Management Comments

• The reporting persons certify that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings by institutional investors in the biotech sector are standard practice for passive investment monitoring and do not typically signal immediate strategic shifts unless the stake crosses the 5% threshold.

Comparison to Industry Standards

• The 4.49% stake is a standard passive position for institutional investment firms in small-cap biotechnology companies.
• The use of private placements and warrants is consistent with typical capital structures for early-stage clinical biotech firms.

Stakeholder Impact

• Shareholders may view the presence of an institutional investor as a sign of market confidence in the company's long-term prospects.

Next Steps

• The reporting persons are required to file amendments to this statement if there are material changes to their ownership percentage.

Key Dates

Keywords

Spruce Biosciences, Alyeska Investment Group, Schedule 13G, Institutional Ownership, Biotech, Equity Disclosure